Free Trial
TSE:IN

InMed Pharmaceuticals (IN) Stock Price, News & Analysis

InMed Pharmaceuticals logo

About InMed Pharmaceuticals Stock (TSE:IN)

Key Stats

Today's Range
N/A
50-Day Range
C$4.19
C$4.19
52-Week Range
N/A
Volume
17,035 shs
Average Volume
29,552 shs
Market Capitalization
C$33.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IN Stock News Headlines

InMed Pharmaceuticals Reports Improved Quarterly Earnings
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
InMed Pharmaceuticals Showcases INM-901 at Biotech Webinar
InMed seeks appeal over Nasdaq delisting notice
3 Penny Stocks to Watch Now, 8/22/24
See More Headlines

IN Stock Analysis - Frequently Asked Questions

Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include Gladstone Land (LAND), Baidu (BIDU), Comstock Resources (CRK), Editas Medicine (EDIT), Enovix (ENVX), HEXO (HEXO) and Merck & Co., Inc. (MRK).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Computer Hardware
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$574,677.00
Book Value
C$0.76 per share

Miscellaneous

Free Float
N/A
Market Cap
C$33.73 million
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (TSE:IN) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners